BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30:593-9. [PMID: 22124109 DOI: 10.1200/JCO.2010.33.8889] [Cited by in Crossref: 256] [Cited by in F6Publishing: 124] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Shin HC, Han W, Moon HG, Park IA, Noh DY. Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. J Breast Cancer 2016;19:268-74. [PMID: 27721876 DOI: 10.4048/jbc.2016.19.3.268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Roberti MP, Arriaga JM, Bianchini M, Quintá HR, Bravo AI, Levy EM, Mordoh J, Barrio MM. Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther. 2012;13:1123-1140. [PMID: 22825326 DOI: 10.4161/cbt.21187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
3 Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. Oncotarget 2017;8:32848-55. [PMID: 28416763 DOI: 10.18632/oncotarget.15858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Hrynchak I, Santos L, Falcão A, Gomes CM, Abrunhosa AJ. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies. IJMS 2021;22:10745. [DOI: 10.3390/ijms221910745] [Reference Citation Analysis]
5 Rinne SS, Orlova A, Tolmachev V. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology. Int J Mol Sci 2021;22:3663. [PMID: 33915894 DOI: 10.3390/ijms22073663] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Stimmer L, Dehay S, Nemati F, Massonnet G, Richon S, Decaudin D, Klijanienko J, Johannes L. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. BMC Cancer 2014;14:916. [PMID: 25476116 DOI: 10.1186/1471-2407-14-916] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
7 Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 2013;108:1358-67. [PMID: 23470469 DOI: 10.1038/bjc.2013.92] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 12.9] [Reference Citation Analysis]
8 De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol. 2014;8:150-158. [PMID: 24220311 DOI: 10.1016/j.molonc.2013.10.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
9 Michel A, Darkwah Oppong M, Rauschenbach L, Dinger TF, Barthel L, Pierscianek D, Wrede KH, Hense J, Pöttgen C, Junker A, Schmidt T, Iannaccone A, Kimmig R, Sure U, Jabbarli R. Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases. Cancers (Basel) 2022;14:1437. [PMID: 35326590 DOI: 10.3390/cancers14061437] [Reference Citation Analysis]
10 Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M. Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model. Int J Mol Sci 2021;22:6336. [PMID: 34199298 DOI: 10.3390/ijms22126336] [Reference Citation Analysis]
11 Martin-Liberal J, Rodon J. Clinical research in small genomically stratified patient populations. Eur J Cancer 2017;80:73-82. [PMID: 28591680 DOI: 10.1016/j.ejca.2017.05.008] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Eralp Y. The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. Transl Oncogenomics 2016;8:1-7. [PMID: 27547031 DOI: 10.4137/TOG.S39410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Signore A, Lauri C, Auletta S, Varani M, Onofrio L, Glaudemans AWJM, Panzuto F, Marchetti P. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers (Basel) 2020;12:E781. [PMID: 32218303 DOI: 10.3390/cancers12040781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Prudkin L, Nuciforo P. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol (Dordr) 2015;38:39-48. [PMID: 25185990 DOI: 10.1007/s13402-014-0192-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
15 Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol 2013;52:1649-56. [PMID: 23327413 DOI: 10.3109/0284186X.2012.754990] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
16 Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, Jenkins R. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer 2016;114:793-800. [PMID: 26908328 DOI: 10.1038/bjc.2016.34] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
17 Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Sci Rep 2021;11:13770. [PMID: 34215766 DOI: 10.1038/s41598-021-92774-z] [Reference Citation Analysis]
18 Matsui A, Murata Y, Masuda N, Mori K, Takahashi M, Yamashiro K, Aogi K, Maeda S, Itou M, Ozaki S, Kuraoka K, Satou Y, Ichihara S, Tokunaga E, Taguchi K, Watanabe T, Suzuki H, Nagayama A, Nishimura R. Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study. Oncotarget 2019;10:5680-9. [PMID: 31620243 DOI: 10.18632/oncotarget.27163] [Reference Citation Analysis]
19 Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol 2014;15:453. [PMID: 25222836 DOI: 10.1186/s13059-014-0453-8] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 16.5] [Reference Citation Analysis]
20 Cai YR, Dong YJ, Wu HB, Liu ZC, Zhou LJ, Su D, Chen XJ, Zhang L, Zhao YL. Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas. Sci Rep 2016;6:23755. [PMID: 27046167 DOI: 10.1038/srep23755] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
21 Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T; TEX Trialists Group. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clin Cancer Res 2017;23:7225-31. [PMID: 28972041 DOI: 10.1158/1078-0432.CCR-17-2301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
22 Soares M, Correia J, Peleteiro MC, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol 2016;37:4053-64. [PMID: 26486327 DOI: 10.1007/s13277-015-4251-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
23 Nami B, Maadi H, Wang Z. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer. Cancers (Basel) 2018;10:E342. [PMID: 30241301 DOI: 10.3390/cancers10100342] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
24 Xi X, Huang XW, Yuan HZ, He C, Ni J, Yang FL. Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases. Oncol Lett 2020;20:273. [PMID: 33014152 DOI: 10.3892/ol.2020.12136] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 2015;6:11652-63. [PMID: 25871474 DOI: 10.18632/oncotarget.3457] [Cited by in Crossref: 182] [Cited by in F6Publishing: 206] [Article Influence: 30.3] [Reference Citation Analysis]
26 Nahta R. New developments in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) 2012;4:53-64. [PMID: 23869176 DOI: 10.2147/BCTT.S24976] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
27 Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging 2018;45:2300-6. [PMID: 30058029 DOI: 10.1007/s00259-018-4099-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
28 Paquette M, Phoenix S, Lawson C, Guérin B, Lecomte R, Tai LH, Turcotte ÉE, Leyton JV. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res 2020;10:69. [PMID: 32592121 DOI: 10.1186/s13550-020-00656-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Lower EE, Khan S, Kennedy D, Baughman RP. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press) 2017;9:515-20. [PMID: 28814897 DOI: 10.2147/BCTT.S137709] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
30 Ring A, Mineyev N, Zhu W, Park E, Lomas C, Punj V, Yu M, Barrak D, Forte V, Porras T, Tripathy D, Lang JE. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget 2015;6:44623-34. [PMID: 26556851 DOI: 10.18632/oncotarget.5977] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
31 Fujii K, Watanabe R, Ando T, Kousaka J, Mouri Y, Yoshida M, Imai T, Nakano S, Fukutomi T. Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions. Biomed Rep 2017;7:535-42. [PMID: 29188058 DOI: 10.3892/br.2017.1003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
32 Boellner S, Becker KF. Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays (Basel) 2015;4:98-114. [PMID: 27600215 DOI: 10.3390/microarrays4020098] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
33 Strand J, Honarvar H, Perols A, Orlova A, Selvaraju RK, Karlström AE, Tolmachev V. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts. PLoS One 2013;8:e70028. [PMID: 23936372 DOI: 10.1371/journal.pone.0070028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
34 Kitahara M, Hozumi Y, Nakamura A, Tachi K, Saitoh H, Iijima T. HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer. Case Rep Oncol 2019;12:473-9. [PMID: 31320870 DOI: 10.1159/000501306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
35 Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012;17:205-16. [PMID: 22865098 DOI: 10.1007/s10911-012-9264-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
36 Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology 2020;296:370-8. [PMID: 32515679 DOI: 10.1148/radiol.2020192828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
37 Jun BH, Guo T, Libring S, Chanda MK, Paez JS, Shinde A, Wendt MK, Vlachos PP, Solorio L. Fibronectin-Expressing Mesenchymal Tumor Cells Promote Breast Cancer Metastasis. Cancers (Basel) 2020;12:E2553. [PMID: 32911713 DOI: 10.3390/cancers12092553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
38 Kutasovic JR, McCart Reed AE, Sokolova A, Lakhani SR, Simpson PT. Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers (Basel) 2020;12:E848. [PMID: 32244556 DOI: 10.3390/cancers12040848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
39 Woo JW, Chung YR, Ahn S, Kang E, Kim EK, Kim SH, Kim JH, Kim IA, Park SY. Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. J Breast Cancer 2019;22:439-52. [PMID: 31598343 DOI: 10.4048/jbc.2019.22.e38] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
40 Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, Chuang JH, Yuan Y. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer 2019;19:96. [PMID: 30665374 DOI: 10.1186/s12885-019-5290-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
41 Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, Steeg PS. Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol 2013;183:1084-95. [PMID: 23895915 DOI: 10.1016/j.ajpath.2013.06.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
42 Kim YW, Seo KJ, Lee SL, Kwon KW, Hur J, An HJ, Ko YH, Kim JS, Won HS. Skeletal muscle metastases from breast cancer: two case reports. J Breast Cancer. 2013;16:117-121. [PMID: 23593092 DOI: 10.4048/jbc.2013.16.1.117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
43 Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W. Molecular Imaging of Biomarkers in Breast Cancer. J Nucl Med 2016;57 Suppl 1:53S-9S. [PMID: 26834103 DOI: 10.2967/jnumed.115.157909] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
44 Wang Y, Sun T, Wan D, Sheng L, Li W, Zhu H, Li Y, Lu J. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. Onco Targets Ther 2015;8:3337-48. [PMID: 26648738 DOI: 10.2147/OTT.S91166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clin Nucl Med 2017;42:912-7. [PMID: 28872549 DOI: 10.1097/RLU.0000000000001820] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
46 Altunay B, Morgenroth A, Mottaghy FM. Use of Radionuclide-Based Imaging Methods in Breast Cancer. Semin Nucl Med 2022:S0001-2998(22)00034-4. [PMID: 35624034 DOI: 10.1053/j.semnuclmed.2022.04.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol 2018;137:295-302. [PMID: 29260362 DOI: 10.1007/s11060-017-2717-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
48 van Uden DJP, van Maaren MC, Strobbe LJA, Bult P, van der Hoeven JJ, Siesling S, de Wilt JHW, Blanken-Peeters CFJM. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res 2019;21:113. [PMID: 31623649 DOI: 10.1186/s13058-019-1201-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
49 Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. Br J Cancer 2018;118:378-87. [PMID: 29169184 DOI: 10.1038/bjc.2017.422] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
50 De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013;10:377-89. [PMID: 23712187 DOI: 10.1038/nrclinonc.2013.80] [Cited by in Crossref: 125] [Cited by in F6Publishing: 116] [Article Influence: 13.9] [Reference Citation Analysis]
51 Ishimine Y, Goto A, Watanabe Y, Yajima H, Nakagaki S, Yabana T, Adachi T, Kondo Y, Kasai K. Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Rep Gastrointest Med 2015;2015:132030. [PMID: 25893119 DOI: 10.1155/2015/132030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
52 Arvelo F, Sojo F, Cotte C. Cancer and the metastatic substrate. Ecancermedicalscience 2016;10:701. [PMID: 28105072 DOI: 10.3332/ecancer.2016.701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol 2016;127:407-14. [PMID: 26909695 DOI: 10.1007/s11060-016-2075-3] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 17.8] [Reference Citation Analysis]
54 Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 2014;16:205. [PMID: 25032257 DOI: 10.1186/bcr3630] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
55 Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 2013;5. [PMID: 24416469 DOI: 10.1007/s12609-013-0125-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
56 Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013;10:437-50. [PMID: 23799370 DOI: 10.1038/nrclinonc.2013.101] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 8.9] [Reference Citation Analysis]
57 Shiino S, Ball G, Syed BM, Kurozumi S, Green AR, Tsuda H, Takayama S, Suto A, Rakha EA. Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat 2021. [PMID: 34613502 DOI: 10.1007/s10549-021-06390-6] [Reference Citation Analysis]
58 Frithiof H, Aaltonen K, Rydén L. A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation. Onco Targets Ther 2016;9:7095-103. [PMID: 27895501 DOI: 10.2147/OTT.S118502] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
59 Zhang S, Li L, Wang T, Bian L, Hu H, Xu C, Liu B, Liu Y, Cristofanilli M, Jiang Z. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer 2016;16:526. [PMID: 27456503 DOI: 10.1186/s12885-016-2578-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
60 Fowler AM, Clark AS, Katzenellenbogen JA, Linden HM, Dehdashti F. Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 2016;57 Suppl 1:75S-80S. [PMID: 26834106 DOI: 10.2967/jnumed.115.157933] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
61 Liwski CR, Castonguay MC, Barnes PJ, Rayson D, Bethune GC. HER2 testing in metastatic breast cancer – Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases? Annals of Diagnostic Pathology 2022. [DOI: 10.1016/j.anndiagpath.2022.151953] [Reference Citation Analysis]
62 Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol 2015;144:713-21. [PMID: 26486734 DOI: 10.1309/AJCPWDEQYCYC92JQ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
63 Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat 2013;141:101-10. [PMID: 23942848 DOI: 10.1007/s10549-013-2658-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
64 Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. PLoS One 2015;10:e0129876. [PMID: 26075403 DOI: 10.1371/journal.pone.0129876] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
65 Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM. Risk factors and survival outcome in cerebral metastatic breast cancer. Med Oncol 2014;31:862. [PMID: 24504842 DOI: 10.1007/s12032-014-0862-2] [Reference Citation Analysis]
66 Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol 2015;17:1241-9. [PMID: 25681308 DOI: 10.1093/neuonc/nov012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
67 Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat 2018;169:523-30. [PMID: 29442264 DOI: 10.1007/s10549-018-4696-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
68 Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134. [PMID: 22738135 DOI: 10.1186/1479-5876-10-134] [Cited by in Crossref: 211] [Cited by in F6Publishing: 208] [Article Influence: 21.1] [Reference Citation Analysis]
69 Fuchikami H, Takeda N, Suno Y, Iijima H, Takagi M, Sato K. Clinical Significance and Problems of Percutaneous Biopsy of Liver Metastasis in Patients with Breast Cancer. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2020;81:14-9. [DOI: 10.3919/jjsa.81.14] [Reference Citation Analysis]
70 Giusti V, Ruzzi F, Landuzzi L, Ianzano ML, Laranga R, Nironi E, Scalambra L, Nicoletti G, De Giovanni C, Olivero M, Arigoni M, Calogero R, Nanni P, Palladini A, Lollini PL. Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. Oncogenesis 2021;10:77. [PMID: 34775465 DOI: 10.1038/s41389-021-00360-9] [Reference Citation Analysis]
71 Ibrahim MF, Hilton J, Addison C, Robertson S, Werier J, Mazzarello S, Vandermeer L, Jacobs C, Clemons M. Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions. J Bone Oncol 2016;5:180-4. [PMID: 28008380 DOI: 10.1016/j.jbo.2016.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
72 Yang Y, Xing Y, Liang C, Hu L, Xu F, Chen Y. Crucial microRNAs and genes of human primary breast cancer explored by microRNA-mRNA integrated analysis. Tumour Biol 2015;36:5571-9. [PMID: 25680412 DOI: 10.1007/s13277-015-3227-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
73 Fabi A, Mottolese M, Segatto O. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. J Mol Med (Berl) 2014;92:681-95. [PMID: 24861025 DOI: 10.1007/s00109-014-1169-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
74 Bachmann C, Schmidt S, Staebler A, Fehm T, Fend F, Schittenhelm J, Wallwiener D, Grischke E. CNS metastases in breast cancer patients: prognostic implications of tumor subtype. Med Oncol 2015;32:400. [PMID: 25433950 DOI: 10.1007/s12032-014-0400-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
75 Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia 2015;17:124-33. [PMID: 25622905 DOI: 10.1016/j.neo.2014.11.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
76 Shin SH, Bode AM, Dong Z. Addressing the challenges of applying precision oncology. NPJ Precis Oncol 2017;1:28. [PMID: 29872710 DOI: 10.1038/s41698-017-0032-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
77 De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget 2018;9:20617-30. [PMID: 29755676 DOI: 10.18632/oncotarget.25041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
78 Yan M, Lv HM, Zhang MW, Cui SD. Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review. Chin J Cancer Res 2014;26:486-92. [PMID: 25232224 DOI: 10.3978/j.issn.1000-9604.2014.08.10] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
79 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
80 O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 2022. [PMID: 35545724 DOI: 10.1007/s10549-022-06602-7] [Reference Citation Analysis]
81 Hou Y, Shen R, Chaudhary S, Gao F, Li Z. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience. Acta Cytol 2016;60:481-9. [PMID: 27681712 DOI: 10.1159/000449400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
82 Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res. 2012;14:R129. [PMID: 23025714 DOI: 10.1186/bcr3324] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
83 Singh A, Sirohi B, Gupta S. Biomarkers in Breast Cancer and the Implications of Their Discordance. Curr Breast Cancer Rep 2013;5:266-74. [DOI: 10.1007/s12609-013-0126-8] [Reference Citation Analysis]
84 Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. [PMID: 17159189 DOI: 10.5858/arpa.2013-0953-sa] [Cited by in Crossref: 612] [Cited by in F6Publishing: 311] [Article Influence: 38.3] [Reference Citation Analysis]
85 Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol 2014;25:605-10. [PMID: 24525703 DOI: 10.1093/annonc/mdt575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
86 Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med 2016;57:1523-8. [PMID: 27151988 DOI: 10.2967/jnumed.115.172031] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 16.7] [Reference Citation Analysis]
87 Duchnowska R, Dziadziuszko R, Trojanowski T, Mandat T, Och W, Czartoryska-Arłukowicz B, Radecka B, Olszewski W, Szubstarski F, Kozłowski W, Jarosz B, Rogowski W, Kowalczyk A, Limon J, Biernat W, Jassem J; Polish Brain Metastasis Consortium. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain. Breast Cancer Res 2012;14:R119. [PMID: 22898337 DOI: 10.1186/bcr3244] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
88 Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med 2016;13:e1002136. [PMID: 27923043 DOI: 10.1371/journal.pmed.1002136] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
89 Han J, Chen Y, Zhao Y, Zhao X, Zhang J, Wang J, Zhang Z. Pre-Clinical Study of the [18F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer. Front Med (Lausanne) 2022;9:803005. [PMID: 35252244 DOI: 10.3389/fmed.2022.803005] [Reference Citation Analysis]
90 Kazama T, Takahara T, Hashimoto J. Breast Cancer Subtypes and Quantitative Magnetic Resonance Imaging: A Systemic Review. Life 2022;12:490. [DOI: 10.3390/life12040490] [Reference Citation Analysis]
91 Zeng J, Piscuoglio S, Aggarwal G, Magda J, Friedlander MA, Murray M, Akram M, Reis-Filho JS, Weigelt B, Edelweiss M. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. Cancer Cytopathol 2020;128:133-45. [PMID: 31883437 DOI: 10.1002/cncy.22226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Vion R, Fontanilles M, Di Fiore F, Clatot F. Place des biopsies liquides dans le diagnostic et la caractérisation moléculaire des cancers du sein: Role of liquid biopsies in the diagnosis and molecular characterization of breast cancer. Bull Cancer 2021;108:11S46-54. [PMID: 34969515 DOI: 10.1016/S0007-4551(21)00636-6] [Reference Citation Analysis]
93 Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, Kalkanis SN, Whitsett TG, Salhia B, Tran NL. Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014;11:203-222. [PMID: 24569448 DOI: 10.1038/nrclinonc.2014.25] [Cited by in Crossref: 147] [Cited by in F6Publishing: 133] [Article Influence: 18.4] [Reference Citation Analysis]
94 Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer 2012;12:555. [PMID: 23176370 DOI: 10.1186/1471-2407-12-555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
95 Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012;18:6784-6791. [PMID: 23092874 DOI: 10.1158/1078-0432.ccr-12-1785] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
96 Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol 2015;26:81-8. [PMID: 25361981 DOI: 10.1093/annonc/mdu498] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
97 Lluch A, Bosch A. Evolution of tumour biology upon progression. Do we know our enemy? Clin Transl Oncol 2012;14:399-400. [PMID: 22634527 DOI: 10.1007/s12094-012-0816-0] [Reference Citation Analysis]
98 Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yotsumoto D, Toi M, Ohno S. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. Jpn J Clin Oncol 2022:hyac022. [PMID: 35296894 DOI: 10.1093/jjco/hyac022] [Reference Citation Analysis]
99 Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2015;33:2695-704. [PMID: 26195705 DOI: 10.1200/JCO.2015.61.1459] [Cited by in Crossref: 169] [Cited by in F6Publishing: 91] [Article Influence: 24.1] [Reference Citation Analysis]
100 Dawood S, Gonzalez-Angulo AM. To biopsy or not to biopsy: is that the only question? Oncologist 2012;17:151-3. [PMID: 22267854 DOI: 10.1634/theoncologist.2011-0432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
101 Griffin N, Marsland M, Roselli S, Oldmeadow C, Attia J, Walker MM, Hondermarck H, Faulkner S. The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer. Biomolecules 2020;10:E1329. [PMID: 32957504 DOI: 10.3390/biom10091329] [Reference Citation Analysis]
102 Aprile G, De Maglio G, Menis J, Casagrande M, Tuniz F, Pisa EF, Fontanella C, Skrap M, Beltrami AC, Fasola G, Pizzolitto S. HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. Int J Mol Sci 2013;14:2370-87. [PMID: 23348930 DOI: 10.3390/ijms14022370] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
103 Godoy-Ortiz A, Alba-Bernal A, Pascual J, Comino-Méndez I, Alba E. Unveiling the Potential of Liquid Biopsy in HER2-Positive Breast Cancer Management. Cancers (Basel) 2022;14:587. [PMID: 35158855 DOI: 10.3390/cancers14030587] [Reference Citation Analysis]
104 Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, Fremd C, Grischke EM, Sinn P, Brucker SY, Schneeweiss A, Hartkopf AD, Wallwiener M. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res Treat 2020;183:137-44. [PMID: 32613540 DOI: 10.1007/s10549-020-05746-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES, Lee J, Nikolinakos PG, Baca AM, Kermani BG, Eltoukhy H, Talasaz A. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One 2015;10:e0140712. [PMID: 26474073 DOI: 10.1371/journal.pone.0140712] [Cited by in Crossref: 399] [Cited by in F6Publishing: 347] [Article Influence: 57.0] [Reference Citation Analysis]
106 Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 2015;12:381-94. [PMID: 25895611 DOI: 10.1038/nrclinonc.2015.73] [Cited by in Crossref: 221] [Cited by in F6Publishing: 217] [Article Influence: 31.6] [Reference Citation Analysis]
107 Goller SS, Markert UR, Fröhlich K. Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature. Geburtshilfe Frauenheilkd 2019;79:618-25. [PMID: 31217630 DOI: 10.1055/a-0880-9295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012;9:542-548. [PMID: 22850751 DOI: 10.1038/nrclinonc.2012.127] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
109 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
110 Malani R, Fleisher M, Kumthekar P, Lin X, Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, Seidman A, Skakodub A, Boire A, DeAngelis LM, Rosenblum M, Raizer J, Pentsova E. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neurooncol 2020;148:599-606. [PMID: 32506369 DOI: 10.1007/s11060-020-03555-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
111 Yuan P, Gao SL. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer. Chronic Dis Transl Med 2017;3:21-32. [PMID: 29063053 DOI: 10.1016/j.cdtm.2017.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
112 Guan X, Liu B, Niu Y, Dong X, Zhu X, Li C, Li L, Yi Z, Sun X, Chen H, Lu S, Ma F. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. Breast 2020;49:261-6. [PMID: 31927339 DOI: 10.1016/j.breast.2019.12.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
113 Brouwer A, De Laere B, van Dam PJ, Peeters D, Van Haver J, Sluydts E, El Moussaoui A, Mendelaar P, Kraan J, Peeters M, Van Laere S, Dirix L. HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques. PLoS One 2019;14:e0220906. [PMID: 31483799 DOI: 10.1371/journal.pone.0220906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
114 Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. Clin Cancer Res 2017;23:4402-15. [PMID: 28351929 DOI: 10.1158/1078-0432.CCR-16-3115] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
115 Islam SS, Uddin M, Noman ASM, Akter H, Dity NJ, Basiruzzman M, Uddin F, Ahsan J, Annoor S, Alaiya AA, Al-Alwan M, Yeger H, Farhat WA. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. EBioMedicine 2019;43:211-24. [PMID: 31085100 DOI: 10.1016/j.ebiom.2019.04.061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
116 Jiang W, Ding Y, Shen Y, Fan L, Zhou L, Li Z, Zheng Y, Zhao P, Liu L, Tong Z. Identifying the clonal origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system using multi-omic platforms. Oncotarget. 2017;8:5016-5025. [PMID: 28008139 DOI: 10.18632/oncotarget.14018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
117 Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, Ren GS, Wu KN, Wang DL, Kong LQ. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 2014;31:798. [PMID: 24307349 DOI: 10.1007/s12032-013-0798-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
118 Ali R, Brown W, Purdy SC, Davisson VJ, Wendt MK. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. Cell Death Dis 2018;9:976. [PMID: 30250119 DOI: 10.1038/s41419-018-1034-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
119 Medress Z, Hayden Gephart M. Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation. Cureus 2015;7:e246. [PMID: 26180670 DOI: 10.7759/cureus.246] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
120 Badve S, Gökmen-Polar Y. Tumor Heterogeneity in Breast Cancer. Adv Anat Pathol 2015;22:294-302. [PMID: 26262511 DOI: 10.1097/PAP.0000000000000074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK. Emerging strategies for treating brain metastases from breast cancer. Cancer Cell 2015;27:163-75. [PMID: 25670078 DOI: 10.1016/j.ccell.2015.01.001] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
122 Milosevic J, Klinge J, Borg AL, Foukakis T, Bergh J, Tobin NP. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer 2013;13:473. [PMID: 24119434 DOI: 10.1186/1471-2407-13-473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
123 Nunes T, Pons T, Hou X, Van Do K, Caron B, Rigal M, Di Benedetto M, Palpant B, Leboeuf C, Janin A, Bousquet G. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer. J Exp Clin Cancer Res 2019;38:306. [PMID: 31299997 DOI: 10.1186/s13046-019-1305-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
124 Ab Mumin N, Ramli Hamid MT, Wong JHD, Rahmat K, Ng KH. Magnetic Resonance Imaging Phenotypes of Breast Cancer Molecular Subtypes: A Systematic Review. Acad Radiol 2022;29 Suppl 1:S89-S106. [PMID: 34481705 DOI: 10.1016/j.acra.2021.07.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209. [PMID: 24887180 DOI: 10.1186/bcr3621] [Cited by in Crossref: 216] [Cited by in F6Publishing: 207] [Article Influence: 27.0] [Reference Citation Analysis]
126 Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W, Zaczek AJ. Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med 2012;10:226. [PMID: 23157797 DOI: 10.1186/1479-5876-10-226] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
127 Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer 2016;16:522. [PMID: 27456970 DOI: 10.1186/s12885-016-2587-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
128 Szarszewska M, Markowska A, Jach R, Marszałek A, Filas V, Bednarek W, Olejek A, Tomczak P, Sajdak S, Nowak-Markwitz E, Jaszczyńska-Nowinka K, Stanisławiak-Rudowicz J, Gryboś A, Chudecka-Głaz A, Gryboś M, Adamska K, Ramlau R, Markowska J, Knapp P. Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study. Adv Med Sci 2019;64:235-40. [PMID: 30822630 DOI: 10.1016/j.advms.2018.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
129 Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 2018;9:5137. [PMID: 30510281 DOI: 10.1038/s41467-018-07608-w] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
130 Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, Sang S, Deng S. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides. Molecules 2021;26:6482. [PMID: 34770887 DOI: 10.3390/molecules26216482] [Reference Citation Analysis]
131 Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med 2022. [PMID: 35031885 DOI: 10.1007/s10238-021-00781-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Liu Y, Liu Q, Wang T, Bian L, Zhang S, Hu H, Li S, Hu Z, Wu S, Liu B, Jiang Z. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer 2013;13:202. [PMID: 23617715 DOI: 10.1186/1471-2407-13-202] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
133 Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014;13:1382-9. [PMID: 24608573 DOI: 10.1158/1535-7163.MCT-13-0482] [Cited by in Crossref: 75] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
134 Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, Bowman RL, Vidone M, Daly L, Nnoli J, Santini D, Taffurelli M, Shih NN, Feldman M, Mao JJ, Colameco C, Chen J, DeMichele A, Fabbri N, Healey JH, Cricca M, Gasparre G, Lyden D, Bonafé M, Bromberg J. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun 2016;7:10442. [PMID: 26858125 DOI: 10.1038/ncomms10442] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 16.8] [Reference Citation Analysis]
135 Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012;7:e33788. [PMID: 22586443 DOI: 10.1371/journal.pone.0033788] [Cited by in Crossref: 389] [Cited by in F6Publishing: 354] [Article Influence: 38.9] [Reference Citation Analysis]
136 Harbeck N, Scharl A, Thomssen C, Müller V. AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. Breast Care (Basel) 2013;8:181-5. [PMID: 24415967 DOI: 10.1159/000353590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
137 Falato C, Tobin NP, Lorent J, Lindström LS, Bergh J, Foukakis T. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Mol Oncol 2016;10:517-25. [PMID: 26651914 DOI: 10.1016/j.molonc.2015.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
138 Nunes T, Hamdan D, Leboeuf C, El Bouchtaoui M, Gapihan G, Nguyen TT, Meles S, Angeli E, Ratajczak P, Lu H, Di Benedetto M, Bousquet G, Janin A. Targeting Cancer Stem Cells to Overcome Chemoresistance. Int J Mol Sci 2018;19:E4036. [PMID: 30551640 DOI: 10.3390/ijms19124036] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
139 Lawal B, Wu ATH, Huang HS. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule. Front Immunol 2022;13:872470. [PMID: 35655775 DOI: 10.3389/fimmu.2022.872470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Boudy AS, Ferrier C, Selleret L, Zilberman S, Arfi A, Sussfeld J, Gligorov J, Richard S, Bendifallah S, Chabbert-Buffet N, Touboul C, Daraï E. Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network. Breast 2020;54:311-8. [PMID: 33271423 DOI: 10.1016/j.breast.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Zhang Y. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 2021;218:107677. [PMID: 32898548 DOI: 10.1016/j.pharmthera.2020.107677] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
142 Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, Smith TR, Brastianos PK, Verhoeff JJC, Lin NU, Broekman MLD. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol 2020;22:1173-81. [PMID: 31970416 DOI: 10.1093/neuonc/noaa013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
143 Yang YF, Liao YY, Yang M, Peng NF, Xie SR, Xie YF. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol 2014;31:214. [PMID: 25216864 DOI: 10.1007/s12032-014-0214-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
144 Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
145 Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, Hayashi N, Yokoyama K, Oshitanai R, Terao M, Morioka T, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y. Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci 2016;107:1730-5. [PMID: 27727484 DOI: 10.1111/cas.13101] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
146 Berghoff AS, Bartsch R, Wöhrer A, Streubel B, Birner P, Kros JM, Brastianos PK, von Deimling A, Preusser M. Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathol 2014;128:879-91. [PMID: 25287912 DOI: 10.1007/s00401-014-1350-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
147 Han CH, Brastianos PK. Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Front Oncol 2017;7:230. [PMID: 28993799 DOI: 10.3389/fonc.2017.00230] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
148 Thigpen J. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. Yearbook of Oncology 2012;2012:75-6. [DOI: 10.1016/j.yonc.2012.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Mol Cancer Ther 2019;18:1115-26. [PMID: 30962322 DOI: 10.1158/1535-7163.MCT-18-0743] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
150 Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget 2017;8:54444-58. [PMID: 28903354 DOI: 10.18632/oncotarget.17088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
151 Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA. Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. J Clin Oncol 2019;37:2601-9. [PMID: 31442103 DOI: 10.1200/JCO.19.00858] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
152 Ishitobi M, Shiba M, Nakayama T, Koyama H, Tamaki Y. Association of human epidermal growth factor receptor 2 status with ipsilateral breast tumor recurrence and resistance to endocrine therapy. Mol Clin Oncol 2015;3:843-6. [PMID: 26171193 DOI: 10.3892/mco.2015.534] [Reference Citation Analysis]
153 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355-64. [PMID: 24048068 DOI: 10.1038/nature12627] [Cited by in Crossref: 700] [Cited by in F6Publishing: 622] [Article Influence: 77.8] [Reference Citation Analysis]